ALTSTATION.IO

Zoetis Inc. (ZTS) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$127.49

Change

+0.60%

Market Cap

$56.50B

Avg Volume

5.2M

Company Overview

Zoetis Inc. develops and sells a range of animal health products, including medicines, vaccines, and diagnostic services. They cater to both livestock and companion animals, targeting veterinarians, livestock producers, and pet owners. Their product portfolio includes parasiticides, anti-infectives, and diagnostics, which are crucial for maintaining the health of various animal species, from cattle to dogs.

Zoetis holds a strong position as a market leader in the animal health sector. They have a comprehensive product lineup and a significant share of the market, which provides a competitive edge. Key competitors include Merck Animal Health and Elanco Animal Health, which also target veterinary and livestock health needs. Market dynamics such as increasing pet ownership and a rising focus on animal health management continue to support Zoetis’s growth, but price competition and regulatory changes could pose challenges.

Currently, Zoetis is in a growth phase, reporting solid revenue increases driven by product innovation and expansion into new markets. In their latest financial reports, the company has demonstrated a year-over-year revenue growth of around 10%, showcasing resilience in a challenging economic climate. Recent strategic partnerships, like the collaboration with Blacksmith Medicines for developing novel antibiotics, highlight their commitment to advancing animal health solutions, positioning them favorably against competitors.

Key Financials

Market Cap

$56.50B

Revenue

$9.40B

EBITDA

$3.99B

Gross Margin

71.7%

Profit Margin

28.2%

Revenue Growth

0.5%

Total Cash

$2.08B

Total Debt

$7.29B

Free Cash Flow

$2.16B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

21.46

Forward P/E

18.74

Beta

0.96

52-Week High

$177.00

52-Week Low

$115.25

EPS

$5.94

50-Day Avg

$124.04

200-Day Avg

$143.68

Price/Book

10.43

Technical Analysis

Over the past 52 weeks, Zoetis Inc. (ZTS) has exhibited a overall downward trend, with a significant decline of approximately 24.8% from its peak near $170 in early February. This downtrend shows a series of lower highs and lower lows, indicating persistent bearish sentiment. Key resistance is evident at the $170 level, while support has formed around $120, where the price seems to bounce back in recent weeks. The stock has displayed a small consolidation pattern just above this support, hinting at potential indecision among investors. Notably, recent momentum has shifted slightly upwards, with the price currently residing at $127.49, which is 6% above the major support at $120 but still significantly below the peak. This positioning within the 52-week range suggests that there may be room for recovery, although caution remains due to the entrenched downtrend.

Recent News and Developments

Here’s a summary of the latest news and developments for Zoetis Inc

(ZTS) stock over the past week:

1. Zoetis Declares Second-Quarter 2026 Dividend Amidst Reduced 2026 Outlook

Zoetis Inc.’s Board of Directors declared a cash dividend of $0.53 per share for the second quarter of 2026. This dividend is payable on June 2, 2026, to shareholders of record as of April 20, 2026. This declaration comes as the company manages a reduced 2026 guidance, attributed to a decrease in veterinary visits from pet owners, although investors continue to highlight the company’s extensive product portfolio and drug pipeline.

2. Anticipation Builds for Zoetis Q4 2025 Earnings Report

Zoetis is scheduled to announce its fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 12, 2026. Analysts are projecting earnings of $1.40 per share and revenue of $2.3612 billion for the quarter. The company has a history of exceeding consensus earnings estimates in the past four quarters.

Market Sentiment and Analyst Recommendations

Bull Case

Zoetis trades at a 21.46 P/E with 16 analysts recommending buy and a $152.81 average price target, implying 20% upside from current levels. The company’s dividend of $0.53 per share signals confidence despite near-term headwinds. Management is launching high-margin innovations like BRD genetic predictions and the Lenivia and Portela drug portfolio, which address real pain points in livestock health and pet osteoarthritis markets. The $56.5B market cap company generates $9.4B in revenue with a fortress balance sheet ($2.08B cash against $7.29B debt), giving it flexibility to weather the current 0.5% revenue growth slowdown. Recent analyst upgrades and the stock’s 6% bounce off the $120 support level suggest institutional buyers see the current pullback as a buying opportunity.

Bear Case

Revenue growth of 0.5% is essentially flat, and management reduced 2026 guidance due to declining veterinary visits from pet owners, a structural headwind that’s harder to spin as temporary. The stock is down 26.2% over the past year and down 24.8% from its February peak near $170, with lower highs and lower lows defining the chart pattern. Regulatory scrutiny around Librela and Solensia creates reputational risk and potential sales headwinds at a time when the company can least afford it. New product launches like Lenivia and Portela are being ramped cautiously with delayed timelines, meaning near-term revenue acceleration won’t happen. At a 21.46 P/E multiple, you’re not getting a discount valuation to justify the execution risk and slowing growth backdrop.

What to Watch

The Q4 2025 earnings report on February 12, 2026 will be critical: watch for actual pet visit trends and whether management maintains or cuts 2026 guidance further. Monitor the ramp trajectory of Lenivia and Portela launches through 2026, particularly early adoption rates among specialist veterinarians. Track whether the BRD genetic prediction product gains meaningful traction in the cattle market, as this is a genuine innovation that could drive livestock segment growth. Watch the regulatory outcome on Librela and Solensia in Europe; any material restrictions or warnings would validate bear concerns. Finally, if the stock breaks decisively below the $120 support level, the downtrend accelerates and the bull thesis breaks. Conversely, a sustained move above $140 would signal the correction is over and the analyst targets become credible.

Analyst Consensus

BUY

Based on 16 analyst opinions

Low Target

$130.00

Mean Target

$152.81

High Target

$200.00

Earnings and Financial Data

Sector

Healthcare

Industry

Drug Manufacturers – Specialty & Generic

Employees

13,800

Earnings & Dividends

Next Earnings

Feb 12, 2026

EPS (Trailing)

$5.94

Dividend Yield

167.0%

Payout Ratio

32.5%

Frequently Asked Questions

Is ZTS a good stock to buy?

Zoetis Inc. (ZTS) has a current P/E ratio of 21.46 and a forward P/E of 18.74, indicating reasonable valuation for growth potential in the healthcare sector. With analysts recommending a BUY and a target price of $152.81, it looks like a solid investment opportunity right now.

What is ZTS’s price target?

The target price for Zoetis Inc. is $152.81 according to analyst recommendations. This represents a potential upside from the current price of $127.49, making it an appealing prospect for investors looking for growth.

Does ZTS pay a dividend?

Yes, Zoetis offers a dividend yield of 167.0%. This is attractive for investors seeking income in addition to capital appreciation from their investments.

What is ZTS’s market cap?

Zoetis has a market cap of $56.50 billion. This positions the company among the larger players in the drug manufacturing industry, reflecting its stability and market presence.

What has been the price range for ZTS over the past year?

ZTS has traded within a 52-week range of $115.25 to $177.00. Currently priced at $127.49, it’s closer to the lower end of that range, suggesting potential for rebound and growth.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.